Back to search

Peptide record

TPDB13312

Antibacterial standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13312
Antibacterial
Anti-infective peptides
AntiBP3 Peptipedia
standard
No
A 22-aa standard natural antibacterial peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
WFGHLYRGITSVVKHVHGLLSG
Physicochemical Analysis
C116H175N33O27
ANDCEQMP
G
2463.87
10.42
5
0
10
+2
-0.58
0.327
110.45
Mammalian: 2.8 hour Yeast: 3 min E.coli: 2 min
6990
283.70
4
Residue Composition
number
0
A
1
R
0
N
0
D
0
C
0
E
0
Q
4
G
3
H
1
I
3
L
1
K
0
M
1
F
0
P
2
S
1
T
1
W
1
Y
3
V
Amino Acid Distribution
A: 0 R: 1 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 3 I: 1 L: 3 K: 1 M: 0 F: 1 P: 0 S: 2 T: 1 W: 1 Y: 1 V: 3
Chemical Descriptors
22
C116H175N33O27
2463.87
10.42
+2
-0.58
0.327
Evidence Records 7 records
Evidence 1 Activity

Activity

MIC
Antibacterial
10.0-21.0 µM

Target

Klebsiella pneumoniae KPC

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 10.0-21.0 uM), ESBL E. coli (MIC 5.2-10.3 uM), XDR A. baumannii (MIC 5.2-10.3 uM), MDR P. aeruginosa (M
Evidence 2 Activity

Activity

MIC
Antibacterial
5.2-10.3 µM

Target

Escherichia coli

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 10.0-21.0 uM), ESBL E. coli (MIC 5.2-10.3 uM), XDR A. baumannii (MIC 5.2-10.3 uM), MDR P. aeruginosa (MIC 10.3-20.6 uM), S. aureus MRSA
Evidence 3 Activity

Activity

MIC
Antibacterial
5.2-10.3 µM

Target

A. baumannii

Source & Reference

NA

Other

active against K. pneumoniae KPC (MIC 10.0-21.0 uM), ESBL E. coli (MIC 5.2-10.3 uM), XDR A. baumannii (MIC 5.2-10.3 uM), MDR P. aeruginosa (MIC 10.3-20.6 uM), S. aureus MRSA (MIC 20.6-41.2 uM), S. epidermidis
Evidence 4 Activity

Activity

MIC
Antibacterial
10.3-20.6 µM

Target

Pseudomonas aeruginosa

Source & Reference

NA

Other

IC 10.0-21.0 uM), ESBL E. coli (MIC 5.2-10.3 uM), XDR A. baumannii (MIC 5.2-10.3 uM), MDR P. aeruginosa (MIC 10.3-20.6 uM), S. aureus MRSA (MIC 20.6-41.2 uM), S. epidermidis (MIC 5.2-10.3 uM), and E. faecalis ant
Evidence 5 Activity

Activity

MIC
Antibacterial
20.6-41.2 µM

Target

Staphylococcus aureus MRSA

Source & Reference

NA

Other

C 5.2-10.3 uM), XDR A. baumannii (MIC 5.2-10.3 uM), MDR P. aeruginosa (MIC 10.3-20.6 uM), S. aureus MRSA (MIC 20.6-41.2 uM), S. epidermidis (MIC 5.2-10.3 uM), and E. faecalis anti-VRE (MIC 5.2-10.3 uM). In total,
Evidence 6 Activity

Activity

MIC
Antibacterial
5.2-10.3 µM

Target

Staphylococcus epidermidis

Source & Reference

NA

Other

IC 5.2-10.3 uM), MDR P. aeruginosa (MIC 10.3-20.6 uM), S. aureus MRSA (MIC 20.6-41.2 uM), S. epidermidis (MIC 5.2-10.3 uM), and E. faecalis anti-VRE (MIC 5.2-10.3 uM). In total, 70 clinical strains were tested an
Evidence 7 Activity

Activity

MIC
Antibacterial
5.2-10.3 µM

Target

Enterococcus faecalis anti-VRE

Source & Reference

NA

Other

C 10.3-20.6 uM), S. aureus MRSA (MIC 20.6-41.2 uM), S. epidermidis (MIC 5.2-10.3 uM), and E. faecalis anti-VRE (MIC 5.2-10.3 uM). In total, 70 clinical strains were tested and the results are expressed as a range.